Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35468322/
Background: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients with long-standing type 2 diabetes to achieve normoglycaemia. We...
Interpretation: The glycaemic efficacy of GIP/GLP-1 receptor agonist tirzepatide in type 2 diabetes results from concurrent improvements in key components of diabetes pathophysiology, namely β-cell function, insulin sensitivity, and glucagon secretion. These effects were large and help to explain the remarkable glucose-lowering ability of...
Add-on value of tirzepatide versus semaglutide
Source : https://www.thelancet.com/journals/landia/article/PIIS2213-8587(22)00116-4/fulltext
Type 2 diabetes is a complex disease with several key defects, including impaired insulin secretion, increased glucagon secretion, and insulin resistance, which is exacerbated by obesity. Thus, besides lifestyle measures,...
Conclusion: Overall, GLP-1 receptor agonists are regarded as crucial in the most recent international guidelines for the management of type 2 diabetes, especially in patients with atherosclerotic cardiovascular disease or obesity.
Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35484580/
doi: 10.1186/s12933-022-01489-6. 1 Ted Rogers Centre for Heart Research, Department of Medicine, University of Toronto, Peter Munk Cardiac Centre, Toronto General Hospital, 200 Elizabeth St, PMCRT 3-904, M5G2C4, Toronto, Canada....
Conclusions: Our study implies that Liraglutide protects the cardiac, cerebral and renal microvasculature against diabetes-induced dysfunction, independent of lowering blood glucose in a type 1 diabetes rat model.
Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004502/
Clin Pharmacol. 2022; 14: 19-26. Exenatide is one of the exendin-based glucagon-like peptide 1 receptor agonists (GLP-1RAs) and is currently available in two formulations, ie, exenatide twice daily (BID), a...
Conclusions: This review provides an overview of the current evidence regarding the clinical efficacy and safety of exenatide QW and discusses the current perspectives on exenatide QW for treatment of T2DM.
-
Type 2 Diabetes Connect4yrThanks for contributing, [~Dr--Hamid--ayeshahameed09@ ] ! What do others think of exenatide twice daily (BID), a short-acting GLP-1RA, vs. exenatide once weekly (QW), a long-acting GLP-1RA?
-
Dr Hamid4yrCan use formulation for pt such as two formulations, ie, exenatide twice daily (BID), a short-acting GLP-1RA, and exenatide once weekly (QW), a long-acting GLP-1RA
Gmail
Source : https://accounts.google.com
Gmail is email that's intuitive, efficient, and useful. 15 GB of storage, less spam, and mobile access.
Show More Comments
Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35408810/
1 Department of Abdominal Surgery, Division of Surgery, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia. 2 Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana,...
Conclusion/Relevance: This review focuses on the pharmacological, clinical, and genetic factors that may influence the response to GLP-1 receptor agonists in the treatment of type 2 diabetes mellitus and obesity.